Guide price only. Final cost is confirmed after assessment.
Ankle replacement is offered at London Cartilage Clinic as the last step of our preserve, repair, regenerate, replace pathway, not the first. End-stage ankle arthritis is treated by replacing the worn joint surfaces with prosthetic components designed to restore movement and relieve pain. Every patient is assessed for biological and joint-preserving alternatives first, because there are usually options to try before replacement is the right answer.
Reviewed byProf Paul Lee MBBch, FRCS (Tr & Orth), PhDLast reviewed 1 May 2026
The preserve, repair, regenerate, replace pathway exists because most ankle arthritis patients have more options than they have been told. We work through that pathway with you before replacement is recommended.
We do offer ankle replacement, and we do it well, but it sits at the bottom of the list of options because it is irreversible. Come and speak to us before you accept that replacement is the only answer.
Ankle replacement recovery follows a structured pathway. Early protection allows the implant to integrate with bone, with progressive loading and rehabilitation guided by clinical and imaging milestones.
The post-operative programme focuses on functional milestones rather than arbitrary timelines. The pace is guided by your progress, not the calendar.
You may have more options than you think
At London Cartilage Clinic we follow a structured clinical framework across four areas of treatment. Before recommending a single procedure, we assess which combination of approaches gives you the best outcome.
Protect what you have. Slow degeneration and manage symptoms.
Fix specific damage. Torn tissue, unstable joints, structural problems.
Rebuild lost tissue. Biological treatments that stimulate new growth.
When other options are exhausted. Joint replacement as a last resort.
Explore the full range of treatments available for your joint. Each hub page shows every option we offer, organised by clinical approach.
Ankle replacement is considered for end-stage ankle arthritis where pain and functional loss have not responded to non-surgical treatment, biological injections, or joint-preserving surgery. Replacement is the bottom of our preserve, repair, regenerate, replace pathway, not the first answer offered.
Many patients with ankle arthritis have biological options including PRP, hyaluronic acid, mFat or stem cell injections, and joint-preserving procedures such as AOAT (ankle osteoplasty with augmented transplantation) for focal defects. We assess every patient against this pathway before recommending replacement.
Modern total ankle replacements are expected to last 10 to 15 years, with newer designs continuing to improve. Longevity depends on implant choice, surgical precision, body weight and activity level. Revision is technically more demanding than for hip or knee replacement, which is one reason we explore preservation-first.
Most patients are non-weight-bearing for two to six weeks depending on implant fixation, with progressive weight-bearing in a boot afterwards. Return to walking unaided typically follows by three months, with full functional recovery taking six to twelve months.
Replacement preserves motion at the ankle joint. Fusion eliminates motion permanently in exchange for a stable, pain-free joint. Replacement suits patients who prioritise mobility; fusion suits patients with very high physical demands or where replacement is not technically feasible. Both options are discussed at consultation if replacement is on the table.
Still have more specific concerns?
Free Discovery CallLondon Cartilage Clinic
Clinical updates, cartilage treatment guidance, and recovery-focused articles from our specialist team.
When ChondroFiller is injected into the joint, it undergoes pH-triggered gelation; the resulting scaffold recruits the body's own repair cells whilst suppressing MMP-13, the primary cartilage-destroying enzyme.
MACI patients return to desk work within two weeks and normal walking by three months, but return to sport takes closer to a year; the delay reflects how long cartilage graft cells must integrate into the surrounding tissue before the repair can withstand athletic demand.
ChondroFiller achieves 70–85% sustained symptom relief across independent clinical cohorts at five-year follow-up through an acellular collagen scaffold that recruits the patient's own progenitor cells.
